Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
479 Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
